Cargando…
Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis
Red cell overproduction is seen in polycythemia vera (PV), a bone marrow myeloproliferative neoplasm characterized by trilinear cell proliferation (WBC, platelets), as well as in secondary erythrocytosis (SE), a group of heterogeneous disorders characterized by elevated EPO gene transcription. We ai...
Autores principales: | Barrios-Ruiz, Alanna, Davila-Gonzalez, Daniel, Fountain, Eric, Cheng, Lee, Verstovsek, Srdan, Rojas-Hernandez, Cristhiam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933419/ https://www.ncbi.nlm.nih.gov/pubmed/35304527 http://dx.doi.org/10.1038/s41598-022-08606-1 |
Ejemplares similares
-
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
por: Nguyen, Eliane, et al.
Publicado: (2021) -
Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019) -
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016) -
Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2023)